Japan’s Fujifilm stops work on Avigan as COVID drug Reuters Oct 17, 2022 In March, Fujifilm had cut short enrolment in a phase-III trial, saying the emergence of the Omicron variant made it tough to…
Appili Therapeutics to partner with Dr Reddy’s, GRA and FUJIFILM for Avigan tablets EP News Bureau Oct 30, 2020 Signs agreement to coordinate and accelerate worldwide development, commercialisation, and distribution of Avigan tablets
Dr Reddy’s Laboratories launches AVIGAN (favipiravir) in India EP News Bureau Aug 19, 2020 Dr Reddy’s AVIGAN comes in a pack of 122 tablets with a two-year shelf life
Dr Reddy’s signs agreement with FUJIFILM and Global Response Aid for Avigan (favipiravir) EP News Bureau Jul 1, 2020 Dr Reddy’s would have exclusive rights for development, selling and distribution of Avigan in India.
Egypt’s Rameda gets requests to export COVID-19 drug – CEO Reuters Jun 25, 2020 The company said earlier this month it had started manufacturing Anviziram, the generic equivalent of the Japanese antiviral…
COVID-19 drug research may drag on into July: Fujifilm Reuters Jun 7, 2020 Researchers have only been able to get around 70 per cent of the patients needed for the trials
Glenmark initiates Phase 3 clinical trials on antiviral Favipiravir for COVID-19 patients in India EP News Bureau May 26, 2020 Glenmark is the first company in India to initiate Phase 3 clinical trials on Favipiravir for COVID-19 patients in India
Fujifilm research into COVID-19 drug spills into June, dashing hope of May approval Reuters May 26, 2020 “The company will continue research into next month or so, and if an application for approval is received from the company, it…
Fujifilm shares fall after report Avigan not showing clear efficacy in some coronavirus trials Reuters May 20, 2020 The data reported to Japan’s health ministry by hospitals treating people showing mild or no symptoms raises doubts about whether…
Russia claims Favipiravir shows promise against coronavirus in early trials Reuters May 14, 2020 Favipiravir is also undergoing trials in India by Glenmark Pharmaceuticals